TNF-alpha Antagonists and Methotrexate in the Treatment of TNF-Mediated Disease
4 Assignments
0 Petitions
Accused Products
Abstract
Methods for treating and/or preventing a TNF-mediated disease in an individual are disclosed. Also disclosed is a composition comprising methotrexate and an anti-tumor necrosis factor antibody. TNF-mediated diseases include rheumatoid arthritis, Crohn'"'"'s disease, and acute and chronic immune diseases associated with transplantation.
5 Citations
57 Claims
-
1-38. -38. (canceled)
- 39. A method of treating an individual suffering from a condition selected from the group consisting of rheumatoid arthritis, juvenile chronic arthritis, ankylosing spondylitis, psoriatic arthritis or Crohn'"'"'s disease, comprising administering to the individual an anti-tumor necrosis factor antibody, or a fragment thereof, which binds specifically to tumor necrosis factor, wherein the anti-tumor necrosis factor antibody is administered in single or multiple doses, as concomitant therapy with methotrexate therapy, and the methotrexate is administered in multiple doses, and wherein the treatment reduces the signs and symptoms associated with the condition.
- 49. A method of treating an individual suffering from rheumatoid arthritis comprising administering to the individual an anti-tumor necrosis factor antibody, wherein the anti-tumor necrosis factor antibody is administered as concomitant therapy to patients receiving methotrexate therapy.
- 51. A method of treating an individual suffering from rheumatoid arthritis comprising administering to the individual an anti-tumor necrosis factor antibody, wherein the anti-tumor necrosis factor antibody is cA2, and is administered as a repeated treatment as concomitant therapy with methotrexate therapy to rheumatoid arthritis patients whose disease is incompletely controlled by methotrexate.
-
57. A method of treating an individual suffering from rheumatoid arthritis comprising administering to the individual an anti-human tumor necrosis factor antibody, or a fragment thereof, which binds specifically to human tumor necrosis factor, wherein the anti-human tumor necrosis factor antibody is administered in single or multiple doses, as concomitant therapy with methotrexate therapy, and the methotrexate is administered in multiple doses, and wherein the treatment reduces the signs and symptoms associated with the condition.
Specification
-
- Resources
Litigation Campaign Assessment
Thank you for your request. You will receive a custom alert email when the Litigation Campaign Assessment is available.
×
-
Current AssigneeThe Kennedy Trust Rheumatology Research
-
Original AssigneeMathilda and Terence Kennedy Institute of Rheumatology Trust
-
InventorsFeldmann, Marc, Maini, Ravinder N.
-
Granted Patent
-
Time in Patent OfficeDays
-
Field of Search
-
US Class Current424/133.1
-
CPC Class CodesA61K 2039/505 comprising antibodiesA61K 2039/545 characterised by the dose, ...A61K 2300/00 Mixtures or combinations of...A61K 31/505 Pyrimidines; Hydrogenated p...A61K 31/519 ortho- or peri-condensed wi...A61K 38/1793 for cytokines; for lymphoki...A61K 39/395 Antibodies agglutinins A61K...A61K 39/39541 against normal tissues, cellsA61K 39/3955 against proteinaceous mater...A61K 45/06 Mixtures of active ingredie...A61P 1/00 Drugs for disorders of the ...A61P 19/02 for joint disorders, e.g. a...A61P 29/00 Non-central analgesic, anti...A61P 37/00 Drugs for immunological or ...A61P 37/06 Immunosuppressants, e.g. dr...C07K 16/241 Tumor Necrosis FactorsC07K 2317/24 containing regions, domains...C07K 2319/00 Fusion polypeptide
